Biotech Values

[DewDiligence]

GTCB strengths B.O.D. with high-pedigree appointments:

[Dr. Bauer in particular is a nice catch. Please note that Bauer has been appointed to the Board of Directors –not the scientific advisory board. The former is responsible for running the company while, at many biotechs, the latter is largely for window dressing.]

http://biz.yahoo.com/bw/041209/95320_1.html

>>
GTC Biotherapeutics Announces the Elections of Kenneth A. Bauer, M.D. and Michael J. Landine to Its Board of Directors

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Dec. 9, 2004--GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced that its Board of Directors has elected Kenneth A. Bauer, M.D of Beth Israel Deaconess Medical Center and Harvard Medical School, and Michael J. Landine of Alkermes, Inc. as additional directors. GTC's Board now has a total of nine directors.

"We are very pleased to welcome both Dr. Kenneth Bauer and Michael Landine to our Board of Directors," stated Geoffrey F. Cox, Ph.D., GTC's Chairman of the Board and Chief Executive Officer. “Dr. Bauer is an internationally recognized authority in the field of thrombosis and haemostasis, providing a strong understanding of the clinical aspects of both ATryn® and our other recombinant blood protein programs. Michael Landine has played an important role in the development of Alkermes over many years and will bring a wealth of experience to GTC, particularly in the areas of finance, accounting, and corporate development."

Background on Dr. Bauer

Dr. Bauer is Director of Thrombosis Clinical Research at Beth Israel Deaconess Medical Center and Associate Professor of Medicine at Harvard Medical School. Dr Bauer's research interests include development of novel laboratory techniques for the detection of prothrombotic states and clinical evaluation of new antithrombotic drugs. Dr. Bauer is the current Chairman of Council for the International Society on Thrombosis and Haemostasis. Dr Bauer has published over 200 original reports, reviews, and book chapters.

Dr. Bauer received his Bachelor and Master of Science degrees from Massachusetts Institute of Technology, and obtained his medical education at Stanford University School of Medicine. He completed subspecialty training in medical oncology and hematology at Dana Farber Cancer Institute and Beth Israel Hospital in Boston. He has been a faculty member at Harvard Medical School since 1982.

Background on Mr. Landine

Mr. Landine currently guides all areas of corporate development at Alkermes, having been appointed Vice President, Corporate Development in 1999. Mr. Landine joined Alkermes in 1988 as Vice President and Chief Financial Officer, a position he held for ten years. Previously, he was the Chief Financial Officer of The Walker Magnetics Group, Inc., an international manufacturer of industrial equipment. Mr. Landine serves on the Board of Directors of a private life sciences company, Expressive Constructs, Inc., and on the Board of Kopin Corporation, Inc., a manufacturer of high definition imaging products. He is also an advisor to the Board of Directors of The Walker Magnetics Group, Inc.

Mr. Landine received a B.S. in Accounting from Bentley College and is a Certified Public Accountant.
<<